Pediatric solid tumors
Conditions
Interventions
Testing Group (Part One):None
Treatment group (Part Two):Based on transcriptomic features and in vivo and in vitro drug sensitivity results, sensitive drugs are screened to form new treatment regimens
Sponsors
Children’s Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for the first part: (1) Children with solid tumors. (2) Sufficient tissue samples for transcriptome sequencing and sufficient PDC or PDO for in vitro drug sensitivity testing. 2. Inclusion criteria for the second part: (1) Children with solid tumors. (2) Sufficient tissue samples for transcriptome sequencing and sufficient PDC or PDO for in vitro drug sensitivity testing. (3) Regarding subsequent individualized intervention treatment: In cases where the tumor becomes refractory or recurrent and cannot be controlled by conventional clinical treatment methods, it will be carried out based on the researcher's judgment and the consent of the subject and their guardian (by signing the informed consent form).
Exclusion criteria
Exclusion criteria: 1. Part One: (1) Children who do not meet the surgical indications; (2) Other conditions were found during the operation, such as severe necrosis of the tissue sample, too small volume, and insufficient remaining tumor tissue after meeting the necessary clinical examinations. 2. Part Two: (1) Children who do not meet the surgical indications; (2) Other conditions such as severe necrosis of tissue samples, too small volume, and insufficient remaining tumor tissue after meeting the necessary clinical examinations are found during the operation; (3) The subjects and their guardians refuse to participate in the subsequent individualized intervention treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comprehensive analysis results of multi-omics characteristics of pediatric solid tumors and drug sensitivity (Part One);The effectiveness rate of individualized treatment plans (Part Two); | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate (Part Two);Progression-free survival time (Part Two);Duration of relief (Part Two);Security (Part Two); | — |
Countries
China
Contacts
Public ContactWang Jinhu, Ying Meidan
Children’s Hospital, Zhejiang University School of Medicine
Outcome results
None listed